Sun Pharma-Moebius Medical anti-osteoarthritis pain drug gets USFDA fast track status

Sun Pharma and Moebius Medical have received fast track designation from the USFDA for their non-opioid therapy MM-II, aimed at treating osteoarthritis knee pain. This designation allows for expedited review and potentially accelerated approval. The companies plan to initiate Phase 3 clinical trials and seek a CE Mark in the European Union.